Approaching Erectile Dysfunction in Dermatology Patients

    July 2013 in “ JAMA Dermatology ”
    Barry Ladizinski, Daniel G. Federman
    Image of study
    TLDR Dermatologists should address erectile dysfunction in patients with skin conditions to improve their quality of life.
    In the article from July 2013, the authors discussed the importance of dermatologists addressing sexual dysfunction, particularly erectile dysfunction (ED), in patients with chronic skin conditions. They highlighted that various skin diseases, such as psoriasis, atopic dermatitis, and eczema, as well as medications like 5α-reductase inhibitors and isotretinoin, can contribute to sexual dysfunction. For instance, a study of 936 psoriasis patients found that 71.3% reported sexual dysfunction due to their condition. The authors suggested that dermatologists are well-positioned to discuss sexual health with patients after establishing trust during skin examinations. They recommended using sexual satisfaction scales and considering both psychological and physiological factors when assessing sexual dysfunction. Treatment options mentioned include psychotherapy, pharmacotherapy, and phosphodiesterase-5 selective inhibitors (PDIs) like sildenafil citrate, tadalafil, and vardenafil hydrochloride. The authors emphasized the need for caution when prescribing PDIs due to potential interactions with other medications and side effects. Addressing sexual dysfunction in dermatology patients can improve their quality of life and potentially reduce healthcare costs by decreasing referrals.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 113 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 8 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community NW5 at 19. How many grafts do I need?

      in Transplants  139 upvotes 1 year ago
      A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

    Similar Research

    5 / 1000+ results